Notices. Notice of public hearings
803 words·~4 min read·
/register/2004/07/07/04-15270A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 3510-08-S DEPARTMENT OF COMMERCE National Oceanic and Atmospheric Administration [I.D. 062904E] Pacific Fishery Management Council; Public Hearings AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce. ACTION: Notice of public hearings. SUMMARY: The Pacific Fishery Management Council (Council) and NMFS will hold two public scoping hearings on alternatives and impacts to be included in an environmental impact statement
(EIS)on dedicated access privileges for the Pacific Coast groundfish trawl fishery. DATES: The hearings will be held Tuesday, July 20, 2004, at 3 p.m. and Tuesday, July 27, 2004, at 3:30 p.m. ADDRESSES: The hearings will be held respectively at the Jim Traynor Conference Room, Building 4, 7600 Sand Point Way, Seattle, WA 98115; telephone:
(206)526-4490 and in the Auditorium of the Mark O. Hatfield Marine Science Center, 2030 S. Marine Science Drive, Newport, OR 97365; telephone:
(541)867-0212. FOR FURTHER INFORMATION CONTACT: Jim Seger, Staff Officer (Economist); Pacific Fishery Management Council, 7700 NE Ambassador Place, Suite 200, Portland, OR 97220-1384; telephone
(503)820-2280. SUPPLEMENTARY INFORMATION: The Council and NMFS announced their intent to hold public scoping meetings on May 24, 2004, (69 FR 29482-29485) when the Council and NMFS issued their notice of intent to prepare an EIS on dedicated access privileges for the Pacific Coast groundfish trawl fishery. The first scoping meeting was held June 13, 2004, in conjunction with a Council meeting in Foster City, CA. The purpose of these hearings is to identify alternatives to be considered and the notable impacts that should be evaluated. These scoping hearings are not intended as a forum for comments in favor of or opposed to the alternatives. A scoping information pamphlet and detailed public scoping information document are available from the Council website ( *www.pcouncil.org* ) or on request from the Council office (see ADDRESSES ). The hearings will be restricted to those issues specifically listed in this document. Special Accommodations The meeting is physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Ms. Carolyn Porter at
(503)820-2280 at least 5 days prior to the meeting date. Dated: July 1, 2004. Alan D. Risenhoover, Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. E4-1487 Filed 7-6-04; 8:45 am] BILLING CODE 3510-22-S DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. 2004-P-039] Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; Atamestane AGENCY: United States Patent and Trademark Office. ACTION: Notice of interim patent term extension. SUMMARY: The United States Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,591,585. FOR FURTHER INFORMATION CONTACT: Karin Ferriter by telephone at
(703)306-3159; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450, Alexandria, VA 22313-1450; by fax marked to her attention at
(703)872-9411, or by e-mail to *Karin.Ferriter@uspto.gov.* SUPPLEMENTARY INFORMATION: Section 156 of title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to a year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On May 21, 2004, patent owner Schering Aktiengesellschaft, timely filed an application under 35 U.S.C. 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,591,585. The patent claims the product atamestane. The application indicates that a New Drug Application for the human drug product atamestane has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially. Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Since it is apparent that the regulatory review period will continue beyond the expiration date of the patent (June 18, 2004), interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. § 156(d)(5) of the term of U.S. Patent No. 4,591,585 is granted for a period of one year from the expiration date of the patent, *i.e.* , until June 18, 2005. Dated: June 24, 2004. Jon W. Dudas, Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office. [FR Doc. 04-15270 Filed 7-6-04; 8:45 am]
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Notices
Notice of public hearings
Cites 1Cited by 0 across 0 sources